North Carolina Cancer Hospital (UNC)

Chapel Hill, North Carolina 27599

0 studies enrolling now · 5 studies all time

What they study most

Bladder Cancer, Metastatic Urothelial Carcinoma (UC), Muscle-Invasive Bladder Carcinoma, Renal Cell Carcinoma

Studies at this site

• Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy — Completed
• ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy — Completed
• Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy — Stopped early
• Neoadjuvant Pazopanib in Renal Cell Carcinoma — Completed
• Single Subject Neratinib in Bladder Cancer (NRR) — NO_LONGER_AVAILABLE